Skip to main
COGT

COGT Stock Forecast & Price Target

COGT Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 40%
Buy 40%
Hold 20%
Sell 0%
Strong Sell 0%

Bulls say

Cogent Biosciences is a biotechnology company with a promising pipeline of precision therapies for genetically defined diseases, including its lead program CGT9486 targeting KIT D816V and other mutations in Systemic Mastocytosis and GIST. With a projected market value of $9.4B based on a discounted cash flow analysis and strong cash position, the company is poised for success pending FDA approvals and positive clinical data. Risks include setbacks in clinical trials and regulatory approval, but the potential for commercial success and pipeline expansion make COGT a compelling investment opportunity.

Bears say

Cogent Biosciences is facing significant risks in achieving their price target and rating, as clinical results from their key CGT9486 program may lead to downward adjustments in market penetration, higher discount rates, and a longer horizon to approval. However, their recent FDA acceptance and priority review for bezuclastinib in combination with sunitinib for previously treated GIST patients is a positive sign, with potential approval likely based on positive Phase 3 PEAK data. Additionally, the company's potential launches in GIST and indolent systemic mastocytosis could lead to significant revenue growth, but the outcome of upcoming regulatory and clinical catalysts remains uncertain.

COGT has been analyzed by 10 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 40% recommend Buy, 20% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Cogent Biosciences, Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Cogent Biosciences, Inc. (COGT) Forecast

Analysts have given COGT a Buy based on their latest research and market trends.

According to 10 analysts, COGT has a Buy consensus rating as of Aug 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $43.40, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $43.40, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Cogent Biosciences, Inc. (COGT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.